News

Kincell Bio announces collaboration to advance Moonlight Bio’s lead cell therapy candidate to clinical study

Kincell Bio, a leading US cell therapy CDMO, is excited to announce a partnership with Moonlight Bio, Inc., a Seattle-based biotech company pioneering advanced T cell therapies for solid tumors. In this partnership, Kincell provides CMC development and GMP manufacturing services to advance...

TileDB, Kepler AI, and Tahoe Therapeutics Partner to Transform Single-Cell Data Analysis with AI-Powered Platform

TileDB, Inc., Kepler AI, and Tahoe Therapeutics today announced a groundbreaking partnership to create the first public-facing platform that enables researchers to run sophisticated AI agent-based queries on massive single-cell datasets at unprecedented scale. This collaboration represents a major...

MindRhythm’s Harmony for Prehospital Large Vessel Occlusion Stroke Identification Submitted for FDA Clearance

MindRhythm Incorporated, a neurodiagnostic company based out of Cupertino, California, today announces it has officially submitted a de novo application to the U.S. Food and Drug Administration (FDA) seeking clearance for its Harmony device designed for prehospital large vessel occlusion (LVO)...

Oculinea, Inc. Enters into Research Agreement with Trican Biotechnology Pipeline

Oculinea, Inc. and Trican Biotechnology based in San Francisco, Ca, and New Taipei City, Taiwan on July 1st, 2025 jointly announced a research collaboration and exclusive option and license agreement to develop a novel ophthalmology implant using antibodies from Trican.  

Landmark UCSF Study Demonstrates Functional Rescue of SCN2A Loss of Function, Underscoring the Potential of Regel Therapeutics' Targeted EpiEditing Platform

The laboratories of Dr. Kevin Bender and Dr. Nadav Ahituv at the University of California, San Francisco, today announced the publication of preclinical proof-of-concept data demonstrating that CRISPR activation restores SCN2A expression and ameliorates disease-related phenotypes in mouse and human...

Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to Develop War-Lock Drug Conjugates and T-Cell Engagers for Improved Conditioning and Certain Autoimmune Diseases

Enlaza Therapeutics, the first covalent biologics platform company, today announced a multi-target drug discovery collaboration with Vertex Pharmaceuticals (“Vertex”) (Nasdaq: VRTX) to utilize Enlaza’s proprietary War-Lock™ technology platform to develop small-format drug conjugates and T-cell...

Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia

The US Food and Drug Administration (FDA) has approved Wayrilz (rilzabrutinib) for adults with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. The approval was based on the pivotal LUNA 3 phase 3 study, in which Wayrilz met the...

Venova Medical Receives FDA IDE Approval for the VENOS-3 Pivotal Study of the Velocity™ Percutaneous AVF System

Venova Medical, a privately held company developing a next-generation technology for the creation of percutaneous arteriovenous fistulas (pAVF) for hemodialysis access, today announced approval from the US Food and Drug Administration (FDA) to initiate its Multicenter Pivotal Study of the Velocity...

Rezo Therapeutics Appoints Derek Hicks as CEO

Rezo Therapeutics, a biotechnology company pioneering the integrated mapping of disease networks for precision therapeutics, today announced that Derek Hicks was appointed CEO. With more than 25 years of leadership in the pharmaceutical and biotech sectors, Derek brings a strong track record of...

BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition

BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced the closing of its previously announced business combination with Helix Acquisition Corp. II (formerly Nasdaq: HLXB) (“Helix”), a special...